{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-102552","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.780931+00:00","generated_at":"2026-05-31T06:40:22.572851+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Invivyd announces PEMGARDA neutralizing activity against dominant variants KP.3.1.1 and LB.1","bullets":["New in vitro data show PEMGARDA neutralizes KP.3.1.1 (42.2% of US cases) and LB.1 variants.","Pemivibart epitope intact across 99.59% of viral sequences since Omicron BA.1.","Data submitted to FDA for timely updates to PEMGARDA Fact Sheet.","Pipeline candidate VYD2311 also shows potent neutralization against contemporary variants.","Company notes 33 variants tested over two years; addresses preliminary non-peer-reviewed reports questioning activity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-102552","json":"https://secwatch.observer/filing/0000950170-24-102552.json","markdown":"https://secwatch.observer/filing/0000950170-24-102552.md","text":"https://secwatch.observer/filing/0000950170-24-102552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024102552/0000950170-24-102552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024102552/ivvd-20240903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:40:22.572851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}